Introduction Solid pharmacological rationale and clinical evidence support the use of a
combination of an inhaled corticosteroid (ICS), a long-acting β2-agonist, and a long-acting …

Tiotropium bromide is the only long‐acting muscarinic antagonist (LAMA) approved for
treatment of patients aged≥ 6 years old with severe asthma who have symptoms of …

Introduction: There is solid evidence that in patients with poorly controlled severe asthma
despite the use of ICS and LABA, the addition of LAMAs, such as tiotropium, significantly …

Severe and poorly controlled asthma still accounts for a great portion of the patients affected.
Disease control and future risk management have been identified by international …

Background When characterizing inhalation products, a comprehensive assessment
including in vitro, pharmacokinetic (PK), and clinical data is required. We conducted a …

Introduction There is increasing evidence that tiotropium, a long-acting muscarinic agent
(LAMA), is useful in the presence of severe-uncontrolled asthma despite the optimization of …

Introduction: Generic inhalers are often perceived as inferior to their branded counterparts;
however, they are safe and effective if they can meet the regulatory requirements. The …

The journey of using anticholinergics in the treatment of asthma started with anticholinergic-
containing plants such as Datura stramonium and Atropa belladonna, followed by …

The burden of uncontrolled asthma in children and adolescents is high. Treatment options
for pediatric patients (aged under 18 years) with asthma are largely influenced by the Global …

Основной целью терапии пациентов с бронхиальной астмой является контроль и
предупреждение возможных рисков в будущем, таких как: обострения заболевания …